Following a setback tests for a leading contender for a potential coronavirus vaccine were put on hold.
A participant in the AstraZeneca vaccine at Oxford University experienced an adverse reaction, it was revealed on Wednesday.
The exact nature of their reaction and its severity were not immediately known.
They are expected to recover fully however.
A spokesperson for AstraZeneca said the pause was “routine.”
“As part of the ongoing randomised, controlled global trials of the Oxford coronavirus vaccine, our standard review process was triggered and we voluntarily paused vaccination to allow review of safety data by an independent committee,” the company said in a statement.
“This is a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials, while it is investigated, ensuring we maintain the integrity of the trials.
“In large trials illnesses will happen by chance but must be independently reviewed to check this carefully.
“We are working to expedite the review of the single event to minimise any potential impact on the trial timeline.
“We are committed to the safety of our participants and the highest standards of conduct in our trials.”
Australia recently filed a letter of intent for the vaccine with Oxford University.
If trials proved successful, Prime Minister Scott Morrison said the drug would be produced locally and distributed here.
It was scheduled to be available beginning in 2021.